Peptide patches are emerging as a convenient, needle-free alternative to traditional peptide injections. Learn how this innovative delivery system could revolutionize the way we approach recovery, immune support, and overall wellness.
On this page
Source Information
Originally published by PR Newswire.Read the original article →
Keep exploring
More on Ozempic
Articles covering Ozempic dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.
8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.
7 min readMore in Peptide Therapy

Revolutionizing Drug Discovery: AI and Peptide Therapy for Longevity
Artificial intelligence is revolutionizing the field of peptide therapy, drastically accelerating drug discovery timelines. This is especially promising for tackling complex diseases like Alzheimer's and advancing the field of longevity research.
3 min read
GLP-1 Weight Loss & The Changing Landscape: Navigating Semaglutide & Beyond
The GLP-1 weight loss market is experiencing significant shifts with new leadership and competitive pressures. This article dives into the latest developments surrounding semaglutide, Ozempic, and Wegovy, and explores the broader impact on health and wellness.
4 min read
GLP-1s & Asthma: How Peptide Therapy Could Improve Metabolic Health & Breathing
New research shows that GLP-1 receptor agonists may significantly reduce asthma exacerbations and the need for steroids in obese patients with asthma. This opens up promising new avenues in metabolic health and asthma management.
3 min read